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Abstract 
 
Bioequivalence studies of drugs with a long half-life require long periods of time for 
pharmacokinetic sampling. The latest update of the European guideline allows the area under 
the curve (AUC) truncated at 72 h to be used as an alternative to AUC0-t as the primary 
parameter. The objective of this study was to evaluate the effect of truncating the AUC at 48, 24 
and 12 h on the acceptance of the bioequivalence criterion as compared with truncation at 72 h 
in bioequivalence trials. The effect of truncated AUC on the within-subject coefficient of 
variation (CVw) and on the ratio of the formulations was also analysed. 
 
Twenty-eight drugs were selected from bioequivalence trials. Pharmacokinetic data were 
analysed using WinNonLin 2.0 based on the trapezoidal method.  Analysis of variance 
(ANOVA) was performed to obtain the ratios and 90% confidence intervals for AUC at 
different time points.  
 
The degree of agreement of AUC0-72 in relation to AUC at 48 and 24 according to the Landis 
and Koch classification was “almost perfect”. Statistically significant differences were observed 
when the CVw of AUCs truncated at 72, 48 and 24 h was compared with the CVw of AUC0-12. 
There were no statistically significant differences in the AUC ratio at any time point. Compared 
to AUC0-72, Pearson’s correlation coefficient for mean AUC, AUC ratio and AUC CVw was 
worse for AUC0-12 than AUC0-24 or AUC0-48. 
 
These preliminary results could suggest that AUC truncation at 24 or 48 h is adequate to 
determine whether two formulations are bioequivalent.  
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Introduction 
 
The European guidelines for conducting bioequivalence studies of immediate-release 
formulations state that two formulations are bioequivalent if the 90% confidence interval (CI) of 
the ratio of the means for the pharmacokinetic parameters (area under the plasma concentration 
curve from administration to the last observed concentration at time t [AUC0-t] and maximum 
plasma concentration [Cmax]) of the test and reference formulations is within the acceptance 
interval of 80.00-125.00% (1, 2). In the case of drugs with a long half-life, the latest update of 
these guidelines proposes truncating the AUC at 72 h (AUC0-72) as an alternative to calculating 
the AUC0-t for comparison of the extent of exposure, as the absorption phase is completed 
during the first 72 h (1). Furthermore, the absorption phase of a drug in its plasma concentration 
versus time is more sensitive and decisive and enables better detection of the differences 
between formulations before the drug is completely eliminated (3). Therefore, a sampling period 
longer than 72 h is not necessary for immediate-release formulations, irrespective of half-life 
(1). 
 
Complete absorption of the drug formulation occurs mostly within the first 24 h; therefore, 
truncation of the AUC at 24 h or 48 h as the primary parameter should be enough. Moreover, 
since absorption is the most relevant parameter in shorter AUCs, these intervals could be more 
sensitive for calculating differences between formulations. 
 
An AUC truncated at under 72 h may be interesting in drugs with a long half-life, not only in 
terms of volunteer participation, but also in terms of compliance with trial visits and in terms of 
the study analysis and costs (3). 
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The purpose of this study was to analyse the effect of truncating the AUC at 48, 24 and 12 h on 
the acceptance of the bioequivalence criterion as compared with truncation at 72 h in 
bioequivalence trials. The effect of truncated AUC on the within-subject coefficient of variation 
(CVw) and on the ratio of the formulations is also evaluated. 
 
 
Materials and methods 
 
Selection criteria for clinical trials 
 
Bioequivalence trials conducted from 2001 until August 2014 at Hospital Universitario de La 
Princesa were analysed on the basis of drug half-life. 
 
The drugs were oral immediate-release drugs whose median half-life of the test and/or reference 
formulation in the clinical trials was ≥ 15 h. This value was chosen as a reference value because 
5 half-lives is sufficient to ensure complete washout (1); consequently, samples could be taken 
up to 72 hours for these drugs. In this case, a total of 15 active substances (28 formulations) 
were analysed, as follows: amlodipine, aripiprazole, citalopram, desloratadine, digoxin, 
donepezil, efavirenz, flunarizine, mirtazapine, nevirapine, olanzapine, rosuvastatin, sertraline, 
tadalafil and telmisartan. The median half-life for the test and reference formulations of the 
trials included are shown in Table 1. 
 
All drugs were presented as tablets, except for aripiprazole, desloratadine and olanzapine, which 
were also presented as orodispersible tablets. Metabolites were not taken into account, and 
sampling was performed at 12, 24, 48 and 72 hours for all selected trials. 
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Study design and subjects 
 
All selected trials shared the same design. They were open-label (blinding was for the analyst 
only), single-dose, randomized, two-period, crossover studies held under fasting conditions. 
 
The sample size was 12 to 48 healthy subjects of both sexes aged between 18 and 55 years. The 
selection criteria were similar for all studies. 
 
The clinical trials were evaluated and approved by the Ethics Committee for Clinical Research 
at Hospital Universitario de La Princesa and the Spanish Agency for Medicines and Medical 
Devices. The studies were conducted in accordance with the Declaration of Helsinki (4) and the 
Guideline for Good Clinical Practice (5). Informed consent was obtained from all participants 
before any procedure was carried out. 
 
Statistical analysis 
 
Pharmacokinetic parameters were calculated using the non-compartmental method, as 
recommended by the European Medicines Agency (EMA) (1), using the pharmacokinetic 
software package WinNonlin Professional Edition, version 2.0 (Scientific Consulting, Inc., 
Cary, USA). The AUC truncated at the various time points was calculated using the linear 
trapezoidal rule. 
 
The pharmacokinetic data of the selected formulations were analysed using the statistical 
package integrated in WinNonLin based on an analysis of variance (ANOVA) of the log-
transformed pharmacokinetic parameters AUC and Cmax and the application of the 90% 
confidence intervals. According to the recommendations of the EMA(1), four factors are 
considered in this ANOVA: sequence, subject within sequence, period and formulation. The 
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bioequivalence acceptance limits were 80-125% for all drugs, except for digoxin, whose 
acceptance limit for the AUC was 90-111% (1, 2). 
 
The degree of agreement of the AUC truncated at various time points was determined by 
calculating the Kappa index according to the Landis and Koch classification (6). Moreover, the 
linear correlation of the mean AUC (test and reference formulations), AUC ratio and AUC CVw 
were calculated using the Pearson correlation coefficient (PCC) with SPSS 19.0. 
 
The CVw was estimated using the formula recommended by the EMA (1) from the mean square 
error obtained from the ANOVA for each pharmacokinetic parameter.  
 
Finally, repeated measures ANOVA was performed using SPSS, version 19.0 to investigate 
significant differences in the results for CVw and in the ratios of the means of the AUC (test and 
reference formulations) at different truncation time points. Adjustment to the normal 
distribution of CVw was necessary and was performed by transforming the data to the Naperian 
logarithm.  
 
 
Results 
 
Acceptance of bioequivalence criteria under the truncated AUC 
 
Figure 1 shows that 4% of studies did not prove to be bioequivalent in the selection of drugs 
with a median half-life ≥15 h. This trial maintained the criterion of not being bioequivalent with 
the AUC truncated at any time point. Bioequivalent drugs maintained the acceptance criterion 
for all four time points, except for one case of aripiprazole tablets and efavirenz tablets, which 
ceased being bioequivalent for AUC0-12. 
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When agreement between AUC0-72 and the other time points (AUC0-48, AUC0-24 and AUC0-12) 
were compared, bioequivalence was “almost perfect” between AUC0-72 and both AUC0-48 and 
AUC0-24, according to the classification of Landis and Koch (6) (Kappa=1) (Table 2). 
Meanwhile, in the case of AUC0-12, the degree of agreement in relation to AUC0-72 was 
“moderate” (6) (Kappa=0.472). Therefore, agreement was better for AUC0-48 and AUC0-24 than 
for AUC0-12.  
 
The PCC for the mean AUC of the test and reference formulations was worse for AUC0-12 than 
for the remaining truncations in relation to the mean AUC0-72. In the case of the mean AUC of 
the test formulation, the PCC was 0.930 for AUC0-12 compared with 0.976 and 0.996 for AUC0-
24 and AUC0-48, respectively. Similar results were found for the AUC mean of the reference 
formulation, namely, a PCC of 0.944 for AUC0-12, 0.976 for AUC0-24 and 0.997 for AUC0-48. 
 
Variation in CVw in truncated AUCs 
 
According to the results of the AUCs truncated at the different time points (Table 3), 
statistically significant differences were observed when the CVw of the AUCs truncated at 72, 
48 and 24 h was compared with the CVw of the AUC0-12.   
 
The PCC in the CVw is worse as we decrease the time of the truncated AUC in relation to 
AUC0-72, namely, 0.969 for AUC0-48, 0.929 for AUC0-24 and 0.862 for AUC0-12. 
 
Variation in ratios in truncated AUCs 
 
No statistically significant differences were observed in the mean of the ratios of AUC for any 
of the truncation time points (Table 4). The PCC for the ratio of AUC0-72 versus AUC0-48, AUC0-
24 and AUC0-12 is worse as the truncation time points decrease: 0.980 for AUC0-48, 0.951 for 
AUC0-24 and 0.909 for AUC0-12. 
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Discussion 
 
Evaluation of AUC truncated at 12, 24 and 48 h compared with the results for AUC0-72 
 
According to the latest update of the EMA guideline, the absorption phase is completed within 
the first 72 hours for immediate-release drugs, regardless of half-life (1). Accordingly, the 
criterion for evaluation of bioequivalence may be sufficient with sampling times of up to 72 h. 
But, most absorption process take place in the first 24 h and the sampling period could be 
shortened. 
 
Our results showed better agreement in the bioequivalence assessment for AUC truncated at 24 
h and 48 h than for AUC truncated at 12 h in relation to AUC0-72 (see Table 2). As shown in 
Figure 1, only two formulations (aripiprazole and efavirenz tablets) ceased being bioequivalent 
with AUC truncated at 12 h. These two factors determine that truncation of the AUC at 12 h 
could be hasty and would not ensure complete absorption of the drug. 
 
While truncation of the AUC at 24 h or 48 h may seem less restrictive than at 72 h, it should be 
noted that, according to the results of Table 3, statistically significant differences were found 
when the CVw of AUC0-12 was compared with the CVw of AUC truncated at 72, 48 and 24 h. In 
addition, the PCC of both the AUC CVw and the AUC ratio of AUC0-72 in relation to the other 
time points shows the worst correlation coefficient for AUC0-12 (see Tables 3 and 4). No 
statistically significant differences were observed in the mean of the ratios for any of the time 
points (Table 4). Therefore, AUC truncated at 24 h and 48 h could also be useful as a criterion 
to establish whether two formulations are bioequivalent. 
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Some authors have demonstrated bioequivalence with truncation at 24 h and/or 48 h using 
studies similar to those used here (7-13). Marzo et al. (13) were able to demonstrate 
bioequivalence for alprazolam (t1/2 = 12.8 h) and naproxen (t1/2 = 16.5 h) with the AUC 
truncated at 12 h. However, truncation of the AUC at less than 72 h was not the main objective 
of any of the studies cited above. Moreover, these studies did not analyse the effect of CVw. 
Oishi et al argue that in the case of immediate release formulations, the elimination phase after 
the time peak concentration depends on the pharmacokinetic property of the active substance 
rather than the dissolution profile of a formulation (14) and we would be focusing on the 
absorption phase of the drug, in which it is easier to detect differences between formulations. 
In addition, when comparing very different formulations, Oishi et al show that the use of AUC 
from zero to the last measurable point (method of calculating AUC in Europe) is more sensitive 
than calculating by extrapolation to the last sampling point (method of calculating AUC in 
Japan) (13). Therefore, truncation of the AUC at 48 h or, even better, at 24 h, might be more 
sensitive for evaluating differences between formulations, since the absorption process has more 
impact on the parameter analysed. In theory, it should be easier to demonstrate bioequivalence 
with AUC0-∞ than with AUC0-72, AUC0-48 or AUC0-24 because of the greater influence of 
elimination, which is not related to the formulation. 
A major limitation of the present analysis is the small number of studies that did not prove 
bioequivalence. Using a simulation of two non-bioequivalent drugs, Mahmood (15) concluded 
that truncating the AUC at 72 h in drugs with a long half-life could be useful, although it could 
lead to drugs that are not bioequivalent being considered as such. Therefore, it would be 
interesting to validate whether our results are consistent in the case of non-bioequivalent drugs. 
Although this study has only analysed the effect of truncated AUC in long half-life drugs in 
crossover designs, it should also be evaluated whether these time points of truncation are valid 
in parallel designs or, on the contrary, whether the time points should be increased, as evidenced 
by El-Tahtawy et al (16). 
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Estimation of the effect on CVw of the AUC truncated at various time points 
 
Najib (17) observed that out of six drugs that proved to be bioequivalent for AUC0-∞, AUC0-t 
and Cmax, four ceased being bioequivalent with the AUC truncated at 72 h. They also realized 
that truncation at 72 h made the CVw increase in relation to the CVw of the AUC at time t and up 
to infinity (regardless of whether they were bioequivalent). This led the authors to argue that the 
parameters AUC0-∞, AUC0-t and Cmax were more sensitive for establishing bioequivalence 
between two formulations, thus making it necessary to consider the method of truncation at 72 h 
recommended by the EMA (1) with caution. The reason they give is that while low CVw with 
the parameters AUC0-∞, AUC0-t and Cmax is valid for determining an adequate sample size, when 
the AUC is truncated, the CVw increases and the sample size may no longer be adequate, with 
the result that the drug becomes non-bioequivalent. This observation should be taken into 
account when deciding to apply this method of truncation as a main variable in a study (17). In 
the study by Najib (17), it is important to remember that not all the drugs used had a long half-
life, as argued by Khandave et al. (3). In addition, they do not specify the formula or the method 
for estimating the CVw. 
The results in Table 3 show statistically significant differences when the CVw of AUC0-12  was 
compared with the CVw of AUC truncated at 72, 48 y 24 h. In addition, the CVw mean was 
higher for AUC0-12 than for the other time points of AUC truncation. This increase in the 
variability could explain why some formulations cease to be bioequivalent with AUC truncation 
at 12 h (see Figure 1); therefore, more subjects could be needed to demonstrate that the 
formulations are bioequivalent (18). The other possibility is that this variation in CVw occurs 
because the whole absorption phase of the drug is not being taken into account. The results are 
also consistent with those obtained in the calculation of PCC for the CVw of AUC0-72 at the 
different time points, in which the correlation was worse for AUC0-12. Consequently, the CVw is 
not affected by truncation at 24, 48 and 72 h. The fact that CVw does not affect truncation at 72 
h was also demonstrated by Khandave et al. (3). 
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In conclusion, our preliminary results could suggest that truncation of the AUC at 24 h or 48 h 
in drugs with a long half-life is sensitive and adequate when determining whether two 
formulations are bioequivalent. Applying these time points in drugs with a long half-life for the 
assessment of bioequivalence reduces not only the number of extractions and site visits, but also 
study costs. However, these studies should be confirmed by analysing a higher and more diverse 
amount of drugs, as well as more non-bioequivalent studies. 
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Table 1. Half-lives for each active substance analysed according to the median resulting 
from the pharmacokinetic analysis and number of volunteers. 
  
Active substance Median t1/2 test (h) Median t1/2 ref. (h) Number of 
volunteers and sex 
Amlodipine tablet 1 34 32 36 (18 M/18 F) 
Amlodipine tablet 2 37 37 36 (18 M/18 F) 
Amlodipine tablet 3  33 33 23 (12 M/11 F) 
Aripiprazole tablet 1 44 49 24 (15M/9F) 
Aripiprazole tablet 2 47 53 26 (18M/12F) 
Aripiprazole tablet 3 50 44 30 (17M/13F) 
Aripiprazole (orodispersible) 1 38 41 34 (15M/19F) 
Aripiprazole (orodispersible) 2 49 52 36 (18M/18F) 
Aripiprazole (orodispersible) 3 50 47 36 (18M/18F) 
Citalopram tablet 33 31 24 (12M/12F) 
Desloratadine tablet 17 16 37 (19M/18F) 
Desloratadine (orodispersible) 17 17 37 (19M/18F) 
Digoxin tablet 88 93 40 (20M/20F) 
Donepezil tablet 62 61 36 (18M/18F) 
Efavirenz tablet 1 55 56 12 (6M/6F) 
Efavirenz tablet 2 62 56 12 (6M/6F) 
Efavirenz tablet 3 60 61 12 (6M/6F) 
Flunarizine tablet 397 288 30 (15M/15F) 
Mirtazapine tablet 24 23 36 (18M/18F) 
Nevirapine tablet 28 31 24 (12M/12F) 
Olanzapine tablet 31 29 30 (15M/15F) 
Olanzapine (orodispersible) 33 33 30 (15M/15F) 
Rosuvastatin tablet 1 15 13 36 (19M/17F) 
Rosuvastatin tablet 2 14 16 36 (17M/19F) 
Sertraline tablet 1 26 26 24 (12M/12F) 
Sertraline tablet 2 23 24 24 (12M/12F) 
Tadalafil tablet 26 25 36 (19M/17F) 
Telmisartan tablet 22 20 48 (22M/26F) 
Median t1/2 test: Median of the half-life of the test formulation; Median t1/2 ref: Median of the 
half-life of the reference formulation; M: male; F: female. 
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Table 2. Degree of agreement of AUC0-72 in relation to AUC at 48, 24 and 12 h 
according to the Landis and Koch classification [5] 
 
 
Measure of agreement 
Kappa 
Landis and Koch Classification 
AUC0-72 vs AUC0-48 1 Almost perfect agreement 
AUC0-72 vs AUC0-24 1 Almost perfect agreement 
AUC0-72 vs AUC0-12 0.472 Moderate 
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Table 3. Means of CVw for AUC0-72, AUC0-48, AUC0-24 and AUC0-12. 
 
   
 Mean and SD of CVw % 
p value in 
relation to 
AUC0-12 
p value in 
relation to 
AUC0-72 
PCC in 
relation to 
AUC0-72 
AUC0-72  10.859 1.454 0.000   
AUC0-48 10.794 1.490 0.000 0.732 0.969 
AUC0-24 11.201 1.499 0.000 0.264 0.929 
AUC0-12 12.692 1.449  0.000 0.868 
 
SD: standard deviation; PCC: Pearson correlation coefficient; N=28 drugs 
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Table 4. Means of the ratios for AUC0-72, AUC0-48, AUC0-24 and AUC0-12.  
 
   
 Mean and SD of ratio  
p value in 
relation to 
AUC0-12 
p value in 
relation to 
AUC0-72 
PCC in 
relation to 
AUC0-72 
AUC0-72  102.494 6.003 0.769   
AUC0-48 102.291 6.864 0.914 0.491 0.980 
AUC0-24 102.067 8.172 0.762 0.471 0.951 
AUC0-12 102.205 9.955  0.769 0.909 
 
 
SD: standard deviation; PCC: Pearson correlation coefficient; N=28 drugs 
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Figure 1. Acceptance of the bioequivalence criterion on the basis of an AUC truncated at 
various time points. The bioequivalence acceptance limits are 80-125% for 90% of confidence 
interval (CI), except for digoxin, whose acceptance limits for AUC are 90-111%. Flunarizine 
was the unique formulation that was never bioequivalent for any of the time points and 
Aripiprazol 1 and Efavirenz 2 tablets ceased being bioequivalent for AUC0-12. 
 
 
 
